People on weight loss medications are being warned not to follow the latest microdosing trend which has been gaining ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Tom Standage, editor of The World Ahead, and Alex Hern, our AI writer, consider the technologies to watch in the coming year.

From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to ...

Thousands of low-income Pennsylvanians will face new barriers to weight-loss drugs like Ozempic under a move quietly ...

As Americans prepare for Christmas, it’s safe to say there were plenty of jokes at family tables this year about the ...

Additionally, in 2025, the U.S. Food and Drug Administration (FDA) approved 11 drugs based on clinical trials in which MSK played a pivotal role. “MSK’s clinical research teams made great progress in ...

In January, Trump RX is scheduled to launch. It will allow people to bypass insurers and other middlemen, and buy discounted drugs directly from manufacturers..

The implications from the design of the clinical GLP-1 agonist trials and studies of caloric restriction are that exercise is ...

New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't taken ...

President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...